# BridgeBio Pharma (BBIO) — Analyst Forecast

BBIO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/bbio/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 22 | 2 | 0 | 24 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $92.00 | $109.46 | $156.00 | 13 |

Last price $67.13 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 15, 2026 | UBS | Initiated Coverage | Buy | $92.00 |
| Oct 7, 2026 | Barclays | Maintained | Overweight | $156.00 |
| Sep 10, 2026 | HC Wainwright & Co. | Maintained | Buy | $120.00 |
| Sep 2, 2026 | HC Wainwright & Co. | Maintained | Buy | $120.00 |
| Sep 1, 2026 | Mizuho | Maintained | Outperform | $110.00 |
| Aug 12, 2026 | JP Morgan | Maintained | Overweight | $111.00 |
| Aug 12, 2026 | Canaccord Genuity | Maintained | Buy | $106.00 |
| Aug 12, 2026 | Truist Securities | Maintained | Buy | $107.00 |
| Aug 11, 2026 | Wells Fargo | Maintained | Overweight | $102.00 |
| Aug 11, 2026 | Piper Sandler | Maintained | Overweight | $115.00 |
| Aug 11, 2026 | Morgan Stanley | Maintained | Overweight | $97.00 |
| Aug 11, 2026 | TD Cowen | Maintained | Buy | $110.00 |
| Aug 11, 2026 | B of A Securities | Maintained | Buy | $104.00 |
| Jul 16, 2026 | Citigroup | Maintained | Neutral | $93.00 |
| Jul 13, 2026 | HC Wainwright & Co. | Maintained | Buy | $120.00 |
| Jun 16, 2026 | Mizuho | Maintained | Outperform | $96.00 |
| Jun 3, 2026 | Canaccord Genuity | Initiated Coverage | Buy | $104.00 |
| May 28, 2026 | HC Wainwright & Co. | Maintained | Buy | $110.00 |
| May 28, 2026 | Morgan Stanley | Maintained | Overweight | $98.00 |
| May 26, 2026 | Raymond James | Downgraded | Outperform → Market Perform | — |

## Frequently Asked Questions

### What is the price target for BBIO stock?

The average 12-month analyst price target for BridgeBio Pharma (BBIO) is $109.46, with a high estimate of $156.00 and a low of $92.00, across 13 analysts.

### Is BBIO a buy, sell, or hold?

Analysts covering BridgeBio Pharma currently average a Buy rating: 22 buy, 2 hold and 0 sell, from 24 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for BBIO?

The average price target of $109.46 implies 63.06% upside from the last price of $67.13.

### What is the latest analyst rating on BBIO?

On Oct 15, 2026, UBS initiated coverage of BridgeBio Pharma at Buy with a price target of $92.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).